Read More Analyst Ratings News Upgrades CL King Upgrades Steven Madden to Buy By Benzinga Newsdesk September 28, 8:29 AM CL King analyst Steven Marotta upgrades Steven Madden (NASDAQ:SHOO) from Neutral to Buy. SHOO
Read More News Tech Rivian Owners Rejoice: Get Your EV Serviced When It Fits Your Schedule Via App By Anan Ashraf August 17, 2:07 AM EV maker Rivian Automotive has offered a new mobile software update that allows its vehicle owners to self-schedule service appointments. RIVN
Read More Analyst Ratings Expert Ratings for Brookfield Infr Partners By Benzinga Insights September 22, 10:00 AM Over the past 3 months, 6 analysts have published their opinion on Brookfield Infr Partners (NYSE:BIP) stock. These… BIP
Read More Biotech General News MiNK Therapeutics, Inc. Announces First Refractory Gastric Cancer Patient Dosed In Phase 2 Trial With Novel Combination Of Co’s Allogeneic INKT Cell Therapy And Agenus’ Botensilimab And Balstilimab By Benzinga Newsdesk February 14, 9:13 AM Dr. Yelena Janjigian, Chief of GI Cancers, Leads Investigator Sponsored Study at Memorial Sloan Kettering Cancer Center Trial is Supported by Stand Up To Cancer as Part of an Initiative to Find Treatments for the INKT